| Full text | |
| Author(s): |
Guerra, Joao V. S.
[1, 2]
;
Dias, Marieli M. G.
[1, 3]
;
Brilhante, Anna J. V. C.
[3, 4]
;
Terra, Maiara F.
[1, 3]
;
Garcia-Arevalo, Marta
[1]
;
Figueira, Ana Carolina M.
[1]
Total Authors: 6
|
| Affiliation: | [1] Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Biosci Natl Lab LNBio, Polo 2 Alta Tecnol R Giuseppe Maximo Scolfaro, BR-13083100 Campinas - Brazil
[2] Univ Estadual Campinas, Fac Pharmaceut Sci, Grad Program Pharmaceut Sci, BR-13083970 Campinas - Brazil
[3] State Univ Campinas Unicamp, Inst Biol, Grad Program Funct & Mol Biol, BR-13083970 Campinas - Brazil
[4] Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Biorenewables Natl Lab LNBR, Polo 2 Alta Tecnol R Giuseppe Maximo Scolfaro, BR-13083100 Campinas - Brazil
Total Affiliations: 4
|
| Document type: | Review article |
| Source: | NUTRIENTS; v. 13, n. 8 AUG 2021. |
| Web of Science Citations: | 3 |
| Abstract | |
Throughout the 20th and 21st centuries, the incidence of non-communicable diseases (NCDs), also known as chronic diseases, has been increasing worldwide. Changes in dietary and physical activity patterns, along with genetic conditions, are the main factors that modulate the metabolism of individuals, leading to the development of NCDs. Obesity, diabetes, metabolic associated fatty liver disease (MAFLD), and cardiovascular diseases (CVDs) are classified in this group of chronic diseases. Therefore, understanding the underlying molecular mechanisms of these diseases leads us to develop more accurate and effective treatments to reduce or mitigate their prevalence in the population. Given the global relevance of NCDs and ongoing research progress, this article reviews the current understanding about NCDs and their related risk factors, with a focus on obesity, diabetes, MAFLD, and CVDs, summarizing the knowledge about their pathophysiology and highlighting the currently available and emerging therapeutic strategies, especially pharmacological interventions. All of these diseases play an important role in the contamination by the SARS-CoV-2 virus, as well as in the progression and severity of the symptoms of the coronavirus disease 2019 (COVID-19). Therefore, we briefly explore the relationship between NCDs and COVID-19. (AU) | |
| FAPESP's process: | 19/14465-1 - Dissection of PPAR gama modulation mechanisms as target to treat diabetes and obesity development |
| Grantee: | Ana Carolina Migliorini Figueira |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 19/10274-7 - Study of the PPARy-coregulators interactions and its relationship with adipogenesis and insulin resistance |
| Grantee: | Marieli Mariano Gonçalves Dias |
| Support Opportunities: | Scholarships in Brazil - Doctorate |